Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research - 1 Jan 2020

Unim Brigid, Pitini Erica, De Vito Corrado, D'Andrea Elvira, Marzuillo Carolina, Villari Paolo

Abstract excerpt

BACKGROUND: Monoclonal antibodies against epidermal growth factor receptor (EGFR) have proved beneficial for the treatment of metastatic colorectal cancer (mCRC), particularly when combined with predictive biomarkers of response. International guidelines recommend anti-EGFR therapy only for RAS (NRAS,KRAS) wild-type tumors because tumors with RAS mutations are unlikely to benefit. OBJECTIVES: We aimed to review...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Clinical Decision-Making

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Drug Costs

Share to Health Care Costs

Share to Pharmacogenomic Testing

Share to Pharmacogenomic Variants

Share to Quality-Adjusted Life Years

Source

Identifiers

PMID: 31952666
DOI: 10.1016/j.jval.2019.07.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review.PMID 31952666Read ↗

Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.Semantic proximity Read ↗

KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.Semantic proximity Read ↗

Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.Semantic proximity Read ↗

Real-world cost-effectiveness of panel-based genomic testing to inform therapeutic decisions for metastatic colorectal cancer.Semantic proximity Read ↗

Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.Semantic proximity Read ↗

KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.Semantic proximity Read ↗

Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.Semantic proximity Read ↗

Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.Semantic proximity Read ↗

Assessment of Treatment Cost-effectiveness Using a Colorectal Cancer Mutation Profile.Semantic proximity Read ↗

Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.Semantic proximity Read ↗

Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample.Semantic proximity Read ↗

Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.